S
Silvia Cantoni
Researcher at Chiesi Farmaceutici S.p.A.
Publications - 52
Citations - 1435
Silvia Cantoni is an academic researcher from Chiesi Farmaceutici S.p.A.. The author has contributed to research in topics: Mesenchymal stem cell & Acute coronary syndrome. The author has an hindex of 16, co-authored 49 publications receiving 1290 citations. Previous affiliations of Silvia Cantoni include University of Bologna & University of Trieste.
Papers
More filters
Journal ArticleDOI
Term amniotic membrane is a high throughput source for multipotent mesenchymal stem cells with the ability to differentiate into endothelial cells in vitro
Francesco Alviano,Valentina Fossati,Cosetta Marchionni,Mario Arpinati,Laura Bonsi,Michele Franchina,Giacomo Lanzoni,Silvia Cantoni,Claudia Cavallini,Francesca Bianchi,Pier Luigi Tazzari,Gianandrea Pasquinelli,Laura Foroni,Carlo Ventura,Alberto Grossi,Gian Paolo Bagnara +15 more
TL;DR: AM-hMSCs may emerge as a remarkable tool for the cell therapy of multiple diseased tissues due to their angiogenic potential and may also pave the way for novel approaches in the development of tissue-engineered vascular grafts which are useful when vascularization of ischemic tissues is required.
Journal ArticleDOI
Hyaluronan mixed esters of butyric and retinoic Acid drive cardiac and endothelial fate in term placenta human mesenchymal stem cells and enhance cardiac repair in infarcted rat hearts.
Carlo Ventura,Silvia Cantoni,Francesca Bianchi,Vincenzo Lionetti,Claudia Cavallini,Ignazio Scarlata,Laura Foroni,Margherita Maioli,Laura Bonsi,Francesco Alviano,Valentina Fossati,Gian Paolo Bagnara,Gianandrea Pasquinelli,Fabio A. Recchia,Alberto Perbellini +14 more
TL;DR: The beneficial effects of HBR-exposed FMhMSCs may be mediated by a large supply of angiogenic and antiapoptotic factors, andFMhMSC differentiation into vascular cells, which may contribute to further development in cell therapy of heart failure.
Journal ArticleDOI
Inhibition of hepatocellular carcinomas in vitro and hepatic metastases in vivo in mice by the histone deacetylase inhibitor HA-But.
Danila Coradini,Sonia Zorzet,Raffaella Rossin,Ignazio Scarlata,C. Pellizzaro,Claudia Turrin,Michele Bello,Silvia Cantoni,Annalisa Speranza,Gianni Sava,Ulderico Mazzi,Alberto Perbellini +11 more
TL;DR: HA-But tends to concentrate in the liver and spleen and appears to be a promising new drug for the treatment of intrahepatic tumor lesions.
Journal ArticleDOI
Butyric and retinoic mixed ester of hyaluronan. A novel differentiating glycoconjugate affording a high throughput of cardiogenesis in embryonic stem cells.
Carlo Ventura,Margherita Maioli,Yolande Asara,Daniela Santoni,Ignazio Scarlata,Silvia Cantoni,Alberto Perbellini +6 more
TL;DR: A novel ester of hyaluronan linked to both butyric and retinoic acid is developed, coaxing pluripotent ES cells into a cardiogenic decision, demonstrating the potential for chemically modifying the gene program of cardiac differentiation in ES cells without the aid of gene transfer technologies.
Journal ArticleDOI
Hyaluronan Mixed Esters of Butyric and Retinoic Acid Affording Myocardial Survival and Repair without Stem Cell Transplantation
Vincenzo Lionetti,Silvia Cantoni,Claudia Cavallini,Francesca Bianchi,Sabrina Valente,Irene Frascari,Elena Olivi,Giovanni Donato Aquaro,Francesca Bonavita,Ignazio Scarlata,Margherita Maioli,Valentina Vaccari,Riccardo Tassinari,A. Bartoli,Fabio A. Recchia,Gianandrea Pasquinelli,Carlo Ventura +16 more
TL;DR: In conclusion, efficient cardiac regenerative therapy can be afforded by HBR without the need of stem cell transplantation or vector-mediated gene delivery.